Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 14.0
(0.65%)
CNY 14.0
(0.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 593.87 Million CNY | 30.38% |
| 2022 | 455.48 Million CNY | -15.0% |
| 2021 | 535.87 Million CNY | 250.14% |
| 2020 | 153.04 Million CNY | -59.49% |
| 2019 | 377.75 Million CNY | 8.78% |
| 2018 | 347.27 Million CNY | 7.31% |
| 2017 | 323.62 Million CNY | 4.1% |
| 2016 | 310.89 Million CNY | 10.2% |
| 2015 | 282.11 Million CNY | 18.52% |
| 2014 | 238.02 Million CNY | 14.82% |
| 2013 | 207.29 Million CNY | 28.39% |
| 2012 | 161.46 Million CNY | 38.86% |
| 2011 | 116.27 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 144.38 Million CNY | -16.12% |
| 2024 Q3 | 141.03 Million CNY | -14.18% |
| 2024 Q2 | 164.34 Million CNY | 13.83% |
| 2023 Q3 | 149.97 Million CNY | 5.35% |
| 2023 Q4 | 172.13 Million CNY | 14.78% |
| 2023 FY | 593.87 Million CNY | 30.38% |
| 2023 Q1 | 129.41 Million CNY | -6.41% |
| 2023 Q2 | 142.36 Million CNY | 10.01% |
| 2022 FY | 455.48 Million CNY | -15.0% |
| 2022 Q4 | 138.27 Million CNY | 13.28% |
| 2022 Q3 | 122.06 Million CNY | 56.08% |
| 2022 Q2 | 78.2 Million CNY | -33.13% |
| 2022 Q1 | 116.94 Million CNY | 6.84% |
| 2021 Q1 | 154.32 Million CNY | 414.51% |
| 2021 Q2 | 146.28 Million CNY | -5.21% |
| 2021 FY | 535.87 Million CNY | 250.14% |
| 2021 Q3 | 125.8 Million CNY | -14.0% |
| 2021 Q4 | 109.46 Million CNY | -12.99% |
| 2020 Q4 | 29.99 Million CNY | -60.23% |
| 2020 Q3 | 75.42 Million CNY | 178.78% |
| 2020 Q2 | 27.05 Million CNY | 31.52% |
| 2020 FY | 153.04 Million CNY | -59.49% |
| 2020 Q1 | 20.57 Million CNY | -83.16% |
| 2019 Q2 | 83.57 Million CNY | 17.94% |
| 2019 FY | 377.75 Million CNY | 8.78% |
| 2019 Q4 | 122.12 Million CNY | 20.68% |
| 2019 Q3 | 101.19 Million CNY | 21.08% |
| 2019 Q1 | 70.86 Million CNY | -40.16% |
| 2018 Q2 | 65.39 Million CNY | -4.0% |
| 2018 Q3 | 95.33 Million CNY | 45.77% |
| 2018 FY | 347.27 Million CNY | 7.31% |
| 2018 Q1 | 68.11 Million CNY | -35.78% |
| 2018 Q4 | 118.42 Million CNY | 24.23% |
| 2017 Q3 | 86.87 Million CNY | 27.83% |
| 2017 Q4 | 106.07 Million CNY | 22.11% |
| 2017 FY | 323.62 Million CNY | 4.1% |
| 2017 Q1 | 62.72 Million CNY | -31.66% |
| 2017 Q2 | 67.95 Million CNY | 8.35% |
| 2016 Q1 | 74.41 Million CNY | -14.67% |
| 2016 Q2 | 66.54 Million CNY | -10.58% |
| 2016 FY | 310.89 Million CNY | 10.2% |
| 2016 Q4 | 91.77 Million CNY | 17.43% |
| 2016 Q3 | 78.15 Million CNY | 17.44% |
| 2015 Q2 | 60.04 Million CNY | -6.4% |
| 2015 Q1 | 64.15 Million CNY | 10.46% |
| 2015 Q4 | 87.21 Million CNY | 23.36% |
| 2015 FY | 282.11 Million CNY | 18.52% |
| 2015 Q3 | 70.69 Million CNY | 17.74% |
| 2014 Q4 | 58.08 Million CNY | -11.41% |
| 2014 Q2 | 60.44 Million CNY | 12.04% |
| 2014 Q1 | 53.94 Million CNY | -4.73% |
| 2014 FY | 238.02 Million CNY | 14.82% |
| 2014 Q3 | 65.56 Million CNY | 8.47% |
| 2013 FY | 207.29 Million CNY | 28.39% |
| 2013 Q4 | 56.62 Million CNY | 9.74% |
| 2013 Q3 | 51.59 Million CNY | 0.0% |
| 2012 FY | 161.46 Million CNY | 38.86% |
| 2011 FY | 116.27 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 40.501% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 76.12% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | -100.043% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | -112.77% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | -79.34% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | -8.147% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -1294.085% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -294.211% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | -97.14% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 537.241% |